Losartan Dose Adjustments for South Asian Patients
Evidence-based guide to losartan dosing in South Asian populations, covering CYP2C9 pharmacogenomics, cardiovascular risk thresholds, and clinical monitoring strategies.
Ethnicity Losartan
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
7articles
3topic areas covered
May 26, 2026latest review
Ethnicity Losartan library
Showing 7 of 7 clinical reviews.
Losartan East Asian Dose Adjustments: What the Pharmacogenomics Actually Show
East Asian patients metabolize losartan differently due to CYP2C9 and CYP3A4 variation, higher rates of poor-metabolizer phenotypes, and lower average body weight. This guide covers evidence-based dose adjustments, pharmacogenomic considerations, and monitoring targets for East Asian patients on losartan.
Losartan East Asian Safety Profile Differences
A clinician-reviewed guide to how East Asian ancestry affects losartan pharmacokinetics, pharmacodynamics, dosing, and safety, including CYP2C9 poor-metabolizer rates, ethnicity-stratified trial data, and evidence-based prescribing adjustments.
Losartan Hispanic / Latino Dose Adjustments: What the Evidence Says
A clinician-reviewed guide to losartan dosing in Hispanic and Latino patients, covering CYP2C9 pharmacogenomics, diabetes-related considerations, LIFE trial subgroup data, and PharmGKB-based prescribing guidance.
Losartan in Black / African Ancestry Patients: Dose Adjustments and Clinical Considerations
Evidence-based guide to losartan dosing, pharmacogenomics, and clinical outcomes in Black and African ancestry patients, including LIFE trial subgroup data, CYP2C9 pharmacogenomics, and JNC/ACC/AHA guideline context.
Losartan in Hispanic / Latino Patients: Safety Profile Differences Explained
A clinical deep-dive into how losartan's pharmacokinetics, pharmacogenomics, and real-world safety profile may differ in Hispanic and Latino patients, with evidence from ethnicity-stratified trial data and population genetics research.
Losartan in Hispanic and Latino Patients: Documented Efficacy Gaps and What the Evidence Shows
A clinical review of losartan pharmacogenomics, ethnicity-stratified trial data, and dosing considerations specific to Hispanic and Latino patients with hypertension or diabetic nephropathy.